| Literature DB >> 26771003 |
Anuradha Kumar1, Ana Guardia2, Gonzalo Colmenarejo3, Esther Pérez2, Ruben R Gonzalez2, Pedro Torres2, David Calvo2, Ruben M Gómez2, Fátima Ortega2, Elena Jiménez2, Raquel C Gabarro2, Joaquín Rullás2, Lluis Ballell2, David R Sherman1,4.
Abstract
Antifolates are widely used to treat several diseases but are not currently used in the first-line treatment of tuberculosis, despite evidence that some of these molecules can target Mycobacterium tuberculosis (Mtb) bacilli in vitro. To identify new antifolate candidates for animal-model efficacy studies of tuberculosis, we paired knowledge and tools developed in academia with the infrastructure and chemistry resources of a large pharmaceutical company. Together we curated a focused library of 2508 potential antifolates, which were then tested for activity against live Mtb. We identified 210 primary hits, confirmed the on-target activity of potent compounds, and now report the identification and characterization of 5 hit compounds, representative of 5 different chemical scaffolds. These antifolates have potent activity against Mtb and represent good starting points for improvement that could lead to in vivo efficacy studies.Entities:
Keywords: antifolate; dihydrofolate reductase; trimetrexate; tuberculosis
Year: 2015 PMID: 26771003 PMCID: PMC4707675 DOI: 10.1021/acsinfecdis.5b00063
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084